Navigation Links
Angiotech to participate in Credit Suisse Global Leveraged Finance Conference
Date:3/20/2008

VANCOUVER, March 20 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, is scheduled to participate in the Credit Suisse Global Leveraged Finance Conference, which is being held March 24-27 in Phoenix, Arizona.

Mr. Thomas Bailey, Angiotech's Chief Financial Officer, is scheduled to present on Wednesday, March 26, beginning at approximately 8:00 am Mountain Time. A question and answer session will immediately follow the presentation.

Presentations at this conference will not be webcast. More information is available on the Angiotech website (http://www.angiotech.com) under the Investors section.

About Angiotech

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit our website at http://www.angiotech.com.

CONTACT: Deirdre Neary, Manager, Investor Relations, Angiotech Pharmaceuticals, Inc., (604) 222-7056, dneary@angio.com


'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. 960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotechs Novel 5-FU Central Venous Catheter
2. Angiotech to participate in Lehman Brothers Healthcare Conference
3. Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006
4. Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter
5. Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting
6. Angiotech announces results for the fourth quarter ended December 31, 2007
7. Angiotech to participate in Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
8. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
9. Angiotech and Symphony Medical Announce Licensing Agreement
10. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
11. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... , Jan 13, 2017 Research and ... Product, Manufacturing, Application - Global Forecast to 2021" report to ... ... 2021 from USD 3.39 Billion in 2016, at a CAGR of ... the basis of product, manufacturing type, and application. Factors such as ...
(Date:1/13/2017)... ... January 13, 2017 , ... FireflySci has been ... found among its diverse customer base. The latest entry in this field is ... including BTX and Bio-Rad. FireflySci is introducing three distinct varieties including a 10x1mm, ...
(Date:1/12/2017)... ... January 12, 2017 , ... Each year, Crain’s Detroit Business News ranks ... that evaluates the patent estate of a company, its impact and significance, and the ... leading the way in technologies that transform energy sources such as low dose X-ray ...
(Date:1/12/2017)... ... January 12, 2017 , ... After ... Lisa Rosendahl’s doctors gave her only a few months to live. Now a ... that has stabilized Rosendahl’s disease and increased both the quantity and quality of ...
Breaking Biology Technology:
(Date:12/7/2016)... PUNE, India , December 7, 2016 According to ... NLP, Machine Learning), Software Tool (Facial Expression, Voice Recognition), Service, Application Area, End ... size is estimated to grow from USD 6.72 Billion in 2016 to USD ... Continue Reading ... ...
(Date:12/7/2016)... LONDON , Dec. 7, 2016   Avanade ... most successful Formula One teams in history, exploit biometric ... pit stop performance and maintain the competitive edge against ... in 2016. Avanade has worked with ... a range of biometric data (heart rate, breathing rate, ...
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. ... has priced an offering of €500.0 million principal amount of ... principal amount of its 2.425% senior unsecured notes due 2026. ... to occur on December 13, 2016, subject to the satisfaction of ... annual basis. The Company intends ...
Breaking Biology News(10 mins):